DeepMed Research

COLORADO DENVER UNIVERSITY OF

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Drug: Nicotine Patch

First Posted Date: 2013-06-28

Last Posted Date: 2016-02-11

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1495

Registration Number: NCT01889771

Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients

Phase 4

Withdrawn

Conditions: Obesity

Interventions: Drug: Standard Dose Group
Drug: Weight Based Group

First Posted Date: 2013-06-26

Last Posted Date: 2017-12-06

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT01886742

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Methyldopa

First Posted Date: 2013-06-21

Last Posted Date: 2022-01-18

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 30

Registration Number: NCT01883804

Locations: 🇺🇸
Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States

Women First: Preconception Maternal Nutrition

Not Applicable

Completed

Conditions: Growth Failure
Morbidity
Mortality
Maternal Malnutrition
Stunting

Interventions: Dietary Supplement: Comprehensive Maternal Nutrition Intervention

First Posted Date: 2013-06-21

Last Posted Date: 2021-07-08

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 7374

Registration Number: NCT01883193

Locations: 🇵🇰
Aga Khan University, Karachi, Pakistan
🇨🇩
Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the
🇬🇹
INCAP, Guatemala City, Guatemala

and more 1 locations

The Efficacy of Analgesic Buffering With Sodium Bicarbonate for the Pediatric Dental Patient

Not Applicable

Withdrawn

Conditions: Pediatric Dentistry

Interventions: Device: Onset Mixing Pen by Onpharma

First Posted Date: 2013-06-21

Last Posted Date: 2015-12-17

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT01883232

Locations: 🇺🇸
Children's Hospital Colorado Dental Clinic, Aurora, Colorado, United States

Window of Opportunity Study Targeting the Inflammatory Milieu

Early Phase 1

Active, not recruiting

Conditions: Stage IB Breast Cancer
Stage II Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IA Breast Cancer
Stage IIIA Breast Cancer
Stage IV Breast Cancer

Interventions: Dietary Supplement: Omega-3 fatty acid
Drug: Celecoxib

First Posted Date: 2013-06-19

Last Posted Date: 2025-01-13

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 42

Registration Number: NCT01881048

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

Not Applicable

Completed

Conditions: Frail Older Adults

Interventions: Behavioral: Progressive Multi-Component Intervention
Behavioral: Usual Care

First Posted Date: 2013-06-07

Last Posted Date: 2017-05-17

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 30

Registration Number: NCT01872637

Locations: 🇺🇸
Arcadia University, Glenside, Pennsylvania, United States
🇺🇸
University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States

Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients

Completed

Conditions: Physical Trauma

First Posted Date: 2013-06-07

Last Posted Date: 2019-10-08

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 50

Registration Number: NCT01871909

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
🇺🇸
San Antonio Military Medical Center, San Antonio, Texas, United States

Phase II Trial for Large ER-Negative Breast Cancers

Phase 2

Completed

Conditions: Malignant Neoplasm of Female Breast

Interventions: Drug: Docetaxel
Drug: Epirubicin
Drug: Capecitabine
Drug: Cyclophosphamide
Radiation: Radiation Therapy

First Posted Date: 2013-06-05

Last Posted Date: 2019-09-24

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 72

Registration Number: NCT01869192

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy

Completed

Conditions: Hematologic Neoplasms

First Posted Date: 2013-06-05

Last Posted Date: 2022-02-09

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT01869218

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy